Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA101 (ACTolog) +/- Atezolizumab in Advanced Solid Cancers
NCT02876510Phase 1Completed
- Sponsor
- Immatics
- Start
- Jun 2017
- Primary completion
- Sep 2021
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of IMA101 in solid tumor (2 arms), sponsored by Immatics. Primary endpoint: Incidence of adverse events at 18 months. Started Jun 2017; status: completed.
02
Drugs
IMA101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02876510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02876510.